Vasopressin and post-traumatic stress disorder

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Post-traumatic stress disorder (PTSD) is a complex psychiatric condition with poorly understood mechanisms, hindering effective therapy.
• Arginine vasopressin (AVP) signaling is increasingly recognized for its potential role in PTSD pathophysiology.
• Current understanding of AVP's involvement in PTSD symptomatology is limited.

Purpose of the Study:

• To investigate the potential role of arginine vasopressin (AVP) signaling in the development and manifestation of PTSD.
• To explore AVP's impact across different PTSD symptom clusters.
• To identify potential therapeutic targets within the AVP system for novel PTSD treatments.

Main Methods:

• Review of existing literature on AVP signaling and PTSD.
• Analysis of rodent models demonstrating AVP's influence on PTSD-like behaviors.
• Examination of AVP system alterations in animal models of PTSD.
• Consideration of pharmacological challenges related to systemic AVP receptor targeting.

Main Results:

• AVP agonists can induce PTSD-like behaviors in laboratory rodents.
• Reduced central AVP signaling in specific rat models ameliorates PTSD-related behavioral parameters.
• Alterations in AVP signaling are observed in distinct brain areas across various animal models of PTSD.
• Peripheral AVP actions, particularly via V1a receptors, can cause side effects like hypotension, complicating systemic treatments.

Conclusions:

• Central AVP signaling is implicated in PTSD symptomatology.
• Targeting brain-specific AVP receptors presents a promising avenue for PTSD treatment development.
• Novel strategies are required to selectively target central AVP receptors, avoiding peripheral side effects.